contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  availableLanguages
  pageUrl
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


coegin-pharma-announces-follicopeptide-as-the-commercial-ingredient-brand-name-for-fol005

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

availableLanguages

pageUrl

imgUrl

description

Coegin Pharma is a Swedish biotechnology company with dermacosmetic projects for hair growth and skin pigmentation, as well as drug candidates for the treatment of heart attacks and leukemia. What the projects have in common is that they are based on patented technology platforms and collaborations with researchers and academics internationally. Coegin Pharma has its headquarters in Lund.

Coegin Pharma

Coegin Pharma's INCI application for FOL005 was approved at the end of May 2024, and an INCI name was granted. This marked a significant milestone in the company's preparations for the global...

<div class="bequoted-body">Coegin Pharma's INCI application for FOL005 was approved at the end of May 2024, and an INCI name was granted. This marked a significant milestone in the company's preparations for the global launch of a product series for hair growth, as an INCI approval is essential for marketing cosmetic products globally. The company has since chosen to trademark the name and can now announce the commercial ingredient brand name "Follicopeptide".The official ingredient name that will appear in ingredient lists is "sh-Oligopeptide-128 SP", and the commercial ingredient brand name is "Follicopeptide"."I am very pleased with the commercial name Follicopeptide and envision that it will signify a premium hair growth product. It will be a mark of quality, indicating that the product is effective and safe," says Jens Eriksson, CEO of Coegin Pharma.INCI stands for "International Nomenclature of Cosmetic Ingredients" and is an international system for naming ingredients used in cosmetic products. This system is used globally, including in the USA, the EU, China, and Japan, which have all been identified as key markets for the launch of Follicopeptide. INCI ensures that ingredients are clearly and consistently labelled, making it easier for consumers and authorities to understand and compare ingredients.For further information, please contact: Jens Eriksson, CEO Email: <a rel="noopener" href="mailto:info@coeginpharma.com">info@coeginpharma.com</a> Phone: +46 72 221 24 21This document is a translation of the original Swedish press release. In case of any discrepancies, the Swedish version shall prevail.About Coegin Pharma Coegin&nbsp;Pharma is a Swedish biotech company with dermacosmetic innovations for hair growth and skin pigmentation, alongside groundbreaking drug candidates for the treatment of myocardial infarction and leukemia.&nbsp;Coegin&nbsp;is planning for the launch of its first product series for hair growth in 2025, followed by a skin pigmentation product in 2026.&nbsp;Coegin Pharma's shares are listed on NGM Nordic SME and Börse Stuttgart, and the company have a registered office in Lund, Sweden.&nbsp;For more information, please visit:&nbsp;<a href="http://www.coeginpharma.com/en">coeginpharma.com/en</a></div><div class="bequoted-files">Attached files<a rel="noopener" href="https://cdn.bequoted.com/media/1/1d611602-5e6c-4f86-bbe5-8d5030eff9e5/240911-Pressrelease.pdf">240911-Pressrelease.pdf</a> </div>

Coegin Pharma announces Follicopeptide as the commercial ingredient brand name for FOL005

Stay up to date with our newsletter